Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Equity Ratio (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Equity Ratio for 9 consecutive years, with 0.76 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 761.5% to 0.76 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.76 through Dec 2025, down 761.5% year-over-year, with the annual reading at 0.76 for FY2025, 761.5% down from the prior year.
  • Equity Ratio hit 0.76 in Q4 2025 for Sutro Biopharma, down from 0.42 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.86 in Q1 2021 to a low of 0.76 in Q4 2025.
  • Historically, Equity Ratio has averaged 0.33 across 5 years, with a median of 0.33 in 2023.
  • Biggest five-year swings in Equity Ratio: surged 60.69% in 2021 and later crashed 761.5% in 2025.
  • Year by year, Equity Ratio stood at 0.74 in 2021, then fell by 27.9% to 0.53 in 2022, then tumbled by 40.4% to 0.32 in 2023, then crashed by 63.77% to 0.12 in 2024, then plummeted by 761.5% to 0.76 in 2025.
  • Business Quant data shows Equity Ratio for STRO at 0.76 in Q4 2025, 0.42 in Q3 2025, and 0.12 in Q2 2025.